As of September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh carries a market capitalization of 175.47B, placing it among publicly traded companies globally. Its enterprise value stands at 163.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 175.47B |
| Enterprise Value | 163.42B |
Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh's next confirmed earnings release is scheduled for February 18, 2027.
| Earnings Date | 2/18/2027 |
As of September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh has 2.67B shares outstanding.
| Shares Outstanding | 2.67B |
As of September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh trades at a trailing price-to-earnings ratio of 12.36. The price-to-sales ratio is 6.72, and the price-to-book ratio stands at 9.40.
| PE Ratio | 12.36 |
| PS Ratio | 6.72 |
| PB Ratio | 9.40 |
| P/TBV Ratio | 9.40 |
| P/FCF Ratio | 46.31 |
| P/OCF Ratio | 37.34 |
As of September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh trades at an EV/EBITDA multiple of 30.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 32.26 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 163.42B versus a market cap of 175.47B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 6.29 |
| EV / EBITDA | 30.52 |
| EV / EBIT | 32.26 |
As of September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.02, indicating elevated leverage, while an interest coverage ratio of 2.83 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.48 |
| Quick Ratio | 2.26 |
| Debt / Equity | 35.02 |
| Debt / EBITDA | 1.22 |
| Interest Coverage | 2.83 |
Over the twelve months ended September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh posted a return on equity (ROE) of 141.97, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 42.41, measuring how efficiently the asset base is converted into earnings. The company generates approximately 10.39M in revenue per employee across its workforce of 2,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.57 indicates how many times Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 141.97 |
| Return on Assets (ROA) | 42.41 |
| Revenue Per Employee | 10.39M |
| Employee Count | 2,500.00 |
| Inventory Turnover | 12.57 |
Over the twelve months ended September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh recorded an income tax benefit of -9.68B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 4.44B, leaving 14.12B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -9.68B |
As of the close on November 16, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh's stock has declined approximately 61.33% over the past 52 weeks. The 50-day moving average sits at 56.68, while the 200-day moving average is 90.28.
| 52-Week Price Change | -61.33% |
| 50-Day Moving Average | 56.68 |
| 200-Day Moving Average | 90.28 |
Over the twelve months ended September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh generated 25.98B in revenue and converted that into 14.12B in net income, yielding earnings per share of 5.14. EBITDA reached 5.35B, while operating income came in at 5.07B.
| Revenue | 25.98B |
| Gross Profit | 20.08B |
| Operating Income | 5.07B |
| Pretax Income | 4.44B |
| Net Income | 14.12B |
| EBITDA | 5.35B |
| EBIT | 5.07B |
| Earnings Per Share (EPS) | 5.14 |
As of September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh holds 18.59B in cash and equivalents against 6.54B in total debt, resulting in a net debt position of -3.84B. Total book value stands at 18.68B, with working capital of 15.80B providing operational flexibility.
| Cash & Cash Equivalents | 18.59B |
| Total Debt | 6.54B |
| Net Debt | -3.84B |
| Equity (Book Value) | 18.68B |
| Book Value Per Share | 6.99 |
| Working Capital | 15.80B |
Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh produced 4.67B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -775.49M in capital expenditures, free cash flow totaled 3.90B - equivalent to 1.47 per share.
| Operating Cash Flow | 4.67B |
| Capital Expenditures | -775.49M |
| Free Cash Flow | 3.90B |
| FCF Per Share | 1.47 |
Over the twelve months ended September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh posted a gross margin of 77.28, reflecting its pricing power and cost economics. The operating margin of 19.50 and net profit margin of 54.34 provide insight into operational efficiency.
| Gross Margin | 77.28 |
| Operating Margin | 19.50 |
| Pretax Margin | 17.08 |
| Profit Margin | 54.34 |
| EBITDA Margin | 20.61 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 2.16, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.34, meaning Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.34 |
| FCF Yield | 2.16 |
As of September 30, 2026, Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh has an Altman Z-Score of 5.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.39 |